You are here: Industry Insights > BAVENCIO

News List

SMC approves Bavencio for bladder cancer pharmatimes
August 11, 2021
Merck and Pfizer’s Bavencio (avelumab) has been approved by the Scottish Medicines Consortium (SMC) for use via NHS Scotland as a first-line maintenance treatment for adult patients with locally advanced or metastatic urothelial carcinoma ...
Preliminary NICE 'no' for Merck's Bavencio pharmatimes
May 07, 2021
The National Institute for Health and Care Excellence (NICE) has issued a preliminary rejection of NHS funds for use of Merck Serono's Bavencio (avelumab) as maintenance treatment of locally advanced or metastatic urothelial cancer.
European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma prnasia
January 25, 2021
Merck and Pfizer Inc. today announced that the European Commission (EC) has approved BAVENCIO® (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are ...
Bavencio, Imbruvica among latest SMC decisions pharmatimes
October 15, 2020
In its latest guidance, the Scottish Medicines Consortium (SMC) has accepted eight new medicines for use by NHS Scotland.
UK bladder cancer patients get early access to Bavencio pharmatimes
September 04, 2020
Merck and Pfizer’s Bavencio (avelumab) is now available under the UK's Early Access to Medicines Scheme (EAMS) giving some patients with bladder cancer the chance to receive treatment with the immunotherapy before its approval in Europe.
NICE green light for immunotherapy Bavencio pharmatimes
September 03, 2020
The National Institute for Health and Care Excellence (NICE) has now published final guidelines endorsing NHS use of Merck and Pfizer's immunotherapy Bavencio (avelumab) in combination with axitinib as a first-line treatment for kidney cancer.
NICE recommends avelumab and axitinib to treat renal cell carcinoma europeanpharmaceuticalreview
August 03, 2020
Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for the treatment of advanced renal cell carcinoma, available on the Cancer Drugs Fund.
NICE backs Bavencio combo for kidney cancer pharmatimes
July 31, 2020
The National Institute for Health and Care Excellence (NICE) has recommended NHS use of Merck and Pfizer's immunotherapy Bavencio (avelumab) in combination with axitinib as a first-line treatment for kidney cancer.
US approves Bavencio for bladder cancer pharmatimes
July 02, 2020
EMD Serono, the biopharmaceutical business of Merck KGaA, and Pfizer announced that the US Food and Drug Administration (FDA) has expanded use of Bavencio (avelumab) to include maintenance treatment of patients ...
EMA to consider expanding use of Merck/Pfizer's Bavencio pharmatimes
June 23, 2020
The European Medicines Agency has validated for review Merck and Pfizer's application to market Bavencio (avelumab) for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC).

Previous page 1 2 3 Next page